2022 American Transplant Congress
Therapeutic Drug Monitoring of Crushed Posaconazole Delayed Release Tablets in Lung Transplant Patients
Northwestern Memorial Hospital, Chicago, IL
*Purpose: Lung transplant patients are at an increased risk for invasive fungal infections and often require prophylaxis post-transplant, routinely including posaconazole at our institution. These…2022 American Transplant Congress
Assessment of Letermovir as Universal Prophylaxis for Cytomegalovirus Infection in Lung Transplant Recipients
*Purpose: Cytomegalovirus (CMV) poses a significant concern in the post-operative management of lung transplant (LT) recipients. Current recommended prophylactic strategies with ganciclovir (GCV) or valganciclovir…2022 American Transplant Congress
Preemptive Therapy in Cytomegalovirus (CMV) Seropositive Donor to Seronegative Recipient Liver Transplants
Transplant, Atrium Health's Carolinas Medical Center, Charlotte, NC
*Purpose: To evaluate if a preemptive therapy strategy can prevent CMV disease and induce CMV seroconversion.*Methods: Observational data collection for CMV D+/R- adult liver transplant…2022 American Transplant Congress
Risk for Loss of Hepatitis B Surface Antibody or Hepatitis B Reactivation in Kidney Transplant Recipients Receiving Lymphocyte Depleting Induction
*Purpose: Although used in over 60% of kidney transplant recipients, the impact of lymphocyte depleting induction on hepatitis B surface antibody (HBsAb) and hepatitis B…2022 American Transplant Congress
Letermovir for Prophylaxis of Cytomegalovirus After Solid Organ Transplantation: A Single-Center, Observational Study
*Purpose: Cytomegalovirus (CMV) infections cause significant complications post-transplant; however, prophylactic medications are often limited by toxicities. Letermovir is a novel terminase inhibitor specific to CMV…2022 American Transplant Congress
Effect of Micafungin Bridging on Prevention of Invasive Candidiasis Post Lung Transplantation
*Purpose: This study aims to determine the effect of micafungin, added as a bridging agent to azole antifungal prophylaxis, in lung transplantation patients with positive…2022 American Transplant Congress
Recurrent Cytomegalovirus and the Role of Secondary Prophylaxis in Heart and Lung Transplant Recipients
*Purpose: This study aimed to describe the incidence of cytomegalovirus (CMV) recurrence in heart and lung transplant recipients and the effect of secondary prophylaxis (SP)…2021 American Transplant Congress
Cost-Effectiveness Analysis of Short-Duration Anti-Viral Prophylaxis for Hepatitis C Positive Donor Kidney Transplants
Virginia Commonwealth University Health System, Richmond, VA
*Purpose: Trials describing 4-12 week courses of direct-acting anti-viral drugs (DAAs) to treat hepatitis C virus (HCV) transmission from infected donors to uninfected kidney transplant…2021 American Transplant Congress
Practice Patterns in Pneumocystis Jirovecii Pneumonia Prophylaxis in Solid Organ and Bone Marrow Transplant Recipients
NYU Langone Transplant Institute, New York, NY
*Purpose: Trimethoprim-sulfamethoxazole (TMP-SMX) is the preferred agent for pneumocystis jirovecii pneumonia (PJP) prophylaxis in solid organ transplant (SOT) and bone marrow transplant (BMT); however, adverse…2021 American Transplant Congress
Utilizing Risk Factors to Guide Prevention of Invasive Fungal Infections in Liver Transplant Recipients
University of Utah Health, Salt Lake City, UT
*Purpose: Invasive fungal infection (IFI) after liver transplant (LT) is associated with significant morbidity and mortality. The optimal antifungal prophylaxis regimen has not been defined.…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 14
- Next Page »